Association Between Prolactinoma and Body Mass Index

Area of Science:

• Endocrinology
• Obesity Research
• Clinical Medicine

Background:

• Rising global obesity rates necessitate understanding contributing factors, including endocrine disorders.
• Prolactinomas are pituitary tumors associated with prolactin overproduction, and their link to weight gain is debated.
• Existing research on weight gain and prolactinomas presents conflicting findings.

Purpose of the Study:

• To investigate whether individuals diagnosed with prolactinomas exhibit higher body mass index (BMI) compared to those without.
• To assess the prevalence of obesity among patients with prolactinomas.

Main Methods:

• Retrospective analysis of patients diagnosed with prolactinomas in an endocrine clinic (2008-2018).
• Inclusion criteria: patients aged 18 years or older with newly diagnosed prolactinomas.
• Comparative data sourced from the National Health and Nutrition Examination Survey (2015-2016).

Main Results:

• Thirty-four cases of prolactinoma met the study criteria; one-third reported weight gain.
• Prolactinoma patients had a significantly higher median BMI (29.8 kg/m² vs. 28.3 kg/m²) compared to the general population.
• A higher prevalence of class II obesity (BMI ≥ 35 kg/m²) was observed in prolactinoma patients (35% vs. 18%).
• Men with prolactinomas showed increased BMI compared to male controls.
• A positive correlation existed between BMI and prolactin levels in prolactinoma patients (R² = 0.4).

Conclusions:

• Weight gain can be an initial symptom of newly diagnosed prolactinomas.
• Patients with prolactinomas demonstrate elevated BMI and a greater prevalence of severe obesity.
• Clinical counseling on weight management and consideration in treatment strategies for prolactinomas are recommended.